上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Darovasertib (Synonyms: LXS196; IDE196) 纯度: 99.68%
Darovasertib (LXS196) 是有效的、选择性的和具有口服活性的蛋白激酶C (PKC) 抑制剂,对 PKCα、PKCθ 和 GSK3β 的 IC50 值分别为 1.9 nM、0.4 nM 和 3.1 μM。Darovasertib 有潜力用于葡萄膜黑素瘤的研究。
Darovasertib Chemical Structure
CAS No. : 1874276-76-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1611 | In-stock | |
2 mg | ¥800 | In-stock | |
5 mg | ¥1550 | In-stock | |
10 mg | ¥2350 | In-stock | |
25 mg | ¥4090 | In-stock | |
50 mg | ¥6100 | In-stock | |
100 mg | ¥9200 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Darovasertib 相关产品
•相关化合物库:
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Epigenetics Compound Library
- Kinase Inhibitor Library
- TGF-beta/Smad Compound Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Reprogramming Compound Library
- Oxygen Sensing Compound Library
- Cytoskeleton Compound Library
- Orally Active Compound Library
生物活性 |
Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research[1][2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[2] |
|
||||||||||||||||
体外研究 (In Vitro) |
Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
Darovasertib (LXS196; compound 9) (15, 30, 75, 150 mg/kg, P.O., mice) shows improved efficacy (regression) in a 92.1 GNAQ uveal melanoma xenograft model in a dose-dependently manner[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
472.47 |
||||||||||||||||
Formula |
C22H23F3N8O |
||||||||||||||||
CAS 号 |
1874276-76-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 25 mg/mL (52.91 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务